Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolterodine Tartrate,Inapplicable
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Unichem Labs Receives US FDA Approval to Market Generic Detrol Tablets
Details : Unichem Laboratories has received ANDA approval for its DETROL® (tolterodine tartrate) Tablets, USP 1 mg and 2 mg from the United States Food and Drug Administration (USFDA) to market a generic version of DETROL® (tolterodine tartrate) tablets of Pfize...
Product Name : Detrol-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2020
Lead Product(s) : Tolterodine Tartrate,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vibegron,Tolterodine Tartrate
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones
Details : Urovant Sciences a family company of Sumitovant announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two Phase 1 trials.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Vibegron,Tolterodine Tartrate
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mirabegron,Tolterodine Tartrate
Therapeutic Area : Urology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2014
Lead Product(s) : Mirabegron,Tolterodine Tartrate
Therapeutic Area : Urology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolterodine Tartrate,Mirabegron
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2013
Lead Product(s) : Tolterodine Tartrate,Mirabegron
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolterodine Tartrate,Desmopressin Acetate
Therapeutic Area : Urology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2012
Lead Product(s) : Tolterodine Tartrate,Desmopressin Acetate
Therapeutic Area : Urology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolterodine Tartrate,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Relative Bioavailability Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2012
Lead Product(s) : Tolterodine Tartrate,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vibegron,Tolterodine Tartrate,Levofloxacin,Cephalexin
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2011
Lead Product(s) : Vibegron,Tolterodine Tartrate,Levofloxacin,Cephalexin
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolterodine Tartrate,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2011
Lead Product(s) : Tolterodine Tartrate,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable